Overview
Long-term Safety of Tafamidis in Subjects With Transthyretin Cardiomyopathy
Status:
Active, not recruiting
Active, not recruiting
Trial end date:
2027-02-16
2027-02-16
Target enrollment:
0
0
Participant gender:
All
All
Summary
Open label study to evaluate tafamidis for the treatment of transthyretin cardiomyopathyPhase:
Phase 3Accepts Healthy Volunteers?
NoDetails
Lead Sponsor:
Pfizer
Criteria
Inclusion Criteria:Cohort A: Completion of 30 months of study treatment on Pfizer Protocol B3461028
Cohort B: Patients in specific countries diagnosed with ATTR-CM who did not previously
participate in Pfizer Study B3461028
Exclusion Criteria:
-Liver and/or heart transplant, or implanted cardiac mechanical assist device